About 90 percent of people with Alzheimer’s disease show behavioral symptoms like agitation, irritability, and anger during the course of the disease. If a caregiver…
Much anticipated Phase 3 data for Alzheimer’s drug lecanemab was presented at CTAD in 2022, showing the drug is as safe as the placebo…
Alzheimer’s disease is a progressive disorder without a cure. While there are drugs which treat many of the symptoms — brain fog, cognitive impairment,…
Update 27 January, 2023: In January 2023, lecanemab was granted accelerated approval by the FDA and made available to patients under the brand name…
A class of medications called cholinesterase inhibitors help to turn back the clock on Alzheimer’s disease’s cognitive symptoms. More than a third people over…
This article was written by Being Patient. Corium, the maker of Adlarity®, a transdermal Alzheimer’s dementia treatment, sponsored the article. Scientists have made substantial…
While scientists don’t know yet what causes Alzheimer’s, beta-amyloid protein plaques remain one of the prime suspects. While many approaches have focused on clearing…
TauRx is currently running a Phase 3 trial called LUCIDITY for what they hope will become the first ever Alzheimer’s pill. But they’ve had…
Here’s a theory: Alzheimer’s biomarker beta-amyloid could — rather than killing the brain — actually be trying to defend it. The provocative idea builds on…
Sometimes I look up and see my future staring at me, wagging her tail. Her name is Beatrice. She’s a 16-year-old cattle dog mix…
Dozens of drugs designed to target and clear beta-amyloid plaques in the brain have failed to prevent or halt the progression of Alzheimer’s disease….
According to an Eisai press release, the U.S. Food and Drug Administration has now granted priority review to a new anti-amyloid drug by Biogen…
On Monday, revealed that a phase 3 study of brexpiprazole — brand name Rexulti — in Alzheimer’s patients showed that the drug for major…
There were more than 140 experimental Alzheimer’s drugs in clinical trials as of the start of 2022. On the one hand, this number inspires…
UPDATE: 3 March 2024, 8:35 P.M. ET. In February 2024, Biogen took Aduhelm off the market, citing financial concerns. Although the drug did receive…